GlassScriptPhysician profile
Michael Abu-Absi
NPI 1750344230
$9,817.79
in general payments reported to CMS, 2019-2025
31 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $1,482 · 2021: $1,817 · 2022: $949 · 2023: $1,805 · 2024: $1,173 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,148 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,147.96 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,100.94 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,713.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $834.47 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $715.34 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $643.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $613.33 | 2019-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $467.76 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $452.25 | 2019-2025 | Jardiance |
| Amgen INC. | $289.73 | 2019-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $263.50 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $231.93 | 2019-2024 | |
| Astellas Pharma US INC | $216.97 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $176.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $171.25 | 2019-2025 | Xarelto, Spravato |
| Kowa Pharmaceuticals America, INC. | $158.84 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $158.65 | 2021-2023 | |
| Davol INC. | $138.01 | 2021 | |
| Shield Therapeutics INC | $93.55 | 2024-2025 | |
| Dexcom, INC. | $73.90 | 2024-2025 | Dexcom G6 Transmitter |
| Strongbridge US INC. | $59.93 | 2019-2020 | |
| Allergan, INC. | $42.72 | 2020 | |
| Abbott Laboratories | $35.84 | 2021-2022 | |
| Esperion Therapeutics, INC. | $25.04 | 2021 | |
| Corcept Therapeutics | $22.92 | 2025 | Korlym |
| Sunovion Pharmaceuticals INC. | $21.04 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.18 | 2025 | Keveyis |
| Ibsa Pharma INC. | $19.18 | 2021 | |
| Hikma Pharmaceuticals USA | $17.25 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.42 | 2023 | Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.41 | 2023 | Xifaxan |
| Vertical Pharmaceuticals, LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Abu-Absi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.